VYNE Therapeutics (NASDAQ:VYNE) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a report published on Monday, Benzinga reports. The firm currently has a $5.75 price target on the stock.

VYNE Therapeutics Stock Performance

VYNE opened at $2.72 on Monday. The firm has a market cap of $38.35 million, a P/E ratio of -0.39 and a beta of 1.26. The business has a 50 day moving average price of $2.51 and a 200 day moving average price of $2.59. VYNE Therapeutics has a twelve month low of $1.67 and a twelve month high of $8.73.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.30. The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.15 million. VYNE Therapeutics had a negative net margin of 6,710.38% and a negative return on equity of 77.46%. As a group, analysts anticipate that VYNE Therapeutics will post -1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Parkman Healthcare Partners LLC purchased a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 696,470 shares of the company’s stock, valued at approximately $1,623,000. Parkman Healthcare Partners LLC owned 4.99% of VYNE Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.